lunes, 2 de noviembre de 2026
A new strategy targets multiple proteins to restore cell function A new approach to protein degradation improved mitochondrial function and neuronal survival in cell models of several mitochondrial disorders. Written byBree Foster, PhD
A new strategy targets multiple proteins to restore cell function
A new approach to protein degradation improved mitochondrial function and neuronal survival in cell models of several mitochondrial disorders.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/a-new-strategy-targets-multiple-proteins-to-restore-cell-function-17609?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_UAdkx5Muc3T8RtFeafWMi2OV74WAUCbvM2iJdn8fXIRMckrP8dHSLyurwVJdX-cJ8PGixokYP3nRo934AV9ua6w3Bbg&_hsmi=446829051&utm_content=446829051&utm_source=hs_email
Most drugs are designed to inhibit a particular protein or interfere with its activity. But in diseases involving widespread cellular dysfunction, targeting a single protein may not be enough. What if, instead, researchers could activate the cell’s own machinery to remove several problematic proteins at once?
In a study published in Science, researchers describe a strategy called stimulated protein degradation (SPD), which activates a cellular protein-clearance system to accelerate the breakdown of multiple proteins. In cellular models of mitochondrial disorders, the approach improved mitochondrial function and helped neurons survive.
Can virtual hearts predict real-world drug risks? From interpreting conflicting laboratory results to modelling underrepresented populations, virtual hearts could help researchers assess cardiac safety earlier in drug development. Written byBree Foster, PhD
Can virtual hearts predict real-world drug risks?
From interpreting conflicting laboratory results to modelling underrepresented populations, virtual hearts could help researchers assess cardiac safety earlier in drug development.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/can-virtual-hearts-predict-real-world-drug-risks-17608
Cardiovascular disease is the leading cause of death worldwide. However, despite massive investment in drug discovery and development, the number of approved drugs has not kept pace. This is partially due to cardiovascular toxicity, as drug-induced cardiac side effects can derail promising candidates during clinical development or lead to serious adverse reactions after approval.
Although preclinical studies can help to identify compounds that disrupt cardiac function, some adverse effects only become apparent when drugs are administered to larger and more diverse patient populations. Differences in biology, drug exposure, and experimental measurements can all influence whether a compound triggers a dangerous cardiac response, making these risks difficult to predict before clinical use.
Psychostimulant misuse and dementia: an evidence-based review Julia Lappin1,2,3,*ORCID iD , Sarah Grattan1 , Shane Darke1,2 , Alys Havard1,2ORCID iD , Emma Devenney
https://www.academia.edu/3071-4087/2/3/10.20935/AcadNeurosci8438
Psychostimulant misuse is associated with vascular pathology and accelerated brain ageing, both of which increase vulnerability to dementia. This review aimed to examine whether psychostimulant misuse is associated with dementia. Searches were conducted in PubMed, Embase, and PsycINFO bibliographic databases from inception to July 2025. For inclusion, studies had to report incident dementia associated with psychostimulant misuse. Two reviewers independently assessed all search results to identify eligible studies, and all included studies were rated for their methodological quality. From 3128 unique retrieved records, 8 articles met the inclusion criteria and were included. One cohort study and seven case studies reported dementia onset in the context of psychostimulant misuse. Although these studies met the inclusion criteria, the predominance of case studies and the heterogeneity in study designs and outcome measures precluded meta-analysis. Psychostimulants involved were methamphetamine, cocaine, khat and caffeine. The quality of studies was variable. There is emerging evidence to support a link between psychostimulant misuse and dementia, in line with biological and neuroimaging evidence of vascular pathology and accelerated brain ageing associated with psychostimulants. Current evidence is largely derived from a single cohort study and further research is needed. Dementia may have an early onset among those misusing psychostimulants due to increased brain vulnerability. Cognitive and functional impairment in those with psychostimulant misuse should be investigated using standardised dementia screening methods in order to assess for this under-detected condition.
https://www.academia.edu/journals/academia-neuroscience-and-brain-research/articles?source=journal-top-nav
Cancer patients are often pressured to end a pregnancy early. They shouldn’t be The research doesn’t support a knee-jerk approach to pregnancy and cancer
https://www.statnews.com/2026/11/02/pregnant-cancer-patients-abortion-early-labor-research/
Cancer patients are often pressured to end a pregnancy early. They shouldn’t be
The research doesn’t support a knee-jerk approach to pregnancy and cancer
By Elyce CardonickNov. 2, 2026
Cardonick is a maternal fetal medicine physician and founder of the Cancer and Pregnancy Registry.
Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival Dupixent Biotech aspires to turn pill into a therapy for multiple immunology and inflammatory disorders
Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival Dupixent
Biotech aspires to turn pill into a therapy for multiple immunology and inflammatory disorders
By Jonathan WosenNov. 2, 2026
West Coast Biotech & Life Sciences Reporter
https://www.statnews.com/2026/11/02/kymera-therapeutics-trial-results-eczema-dupixent-rival/
Suscribirse a:
Entradas (Atom)
.jfif)
